Projects
Proteomics
Clinical proteomics
We will perform differential proteome studies in order to detect new biomarkers. For this purpose profiles of proteins from different stages of a disease will be compared to one another. This will require the microdissection of pathologically relevant patient samples in a first step, and following, the analysis thereof, using the sensitive DIGE (Fluorescence 2D Difference Gel Electrophoresis)-saturation technology. The combination of both technologies allows for a proteome analysis of cell populations from human tissue that is relevant to specific diseases. In addition to this, the same samples will be analyzed with a complementary technology based on mass-spectrometry. The so called label-free proteomics for the quantitative analysis of complex protein samples allows for the fully automatic, highly sensitive analysis of larger collectives of patients. Differential proteins will be tested for their suitability as biomarkers in further validation tests. To this end, immunohistochemistry (Tissuearrays) of the tissue and Westernblots of blood serums from more than 100 patients will be carried out. For proteins with a high potential as possible biomarkers, ELISA-tests will be developed, which allow for the analysis of many hundred blood samples.
Contact: